Synthesis and biological evaluation of alkyl, alkoxy, alkylthio, or amino-substituted 2,3-dihydro-1,5-benzothiazepin-4(5H)-ones

Chemical and Pharmaceutical Bulletin

Volumn 45, Issue 6, 1997, Pages 1008-1026

  Inoue, Hirozumi ^a   Konda, Mikihiko ^a   Hashiyama, Tomiki ^a   Otsuka, Hisao ^a   Watanabe, Akishige ^a   Gaino, Mitsunori ^a   Takahashi, Kaoru ^a   Date, Tadamasa ^a   Okamura, Kimio ^a   Takeda, Mikio ^a   Narita, Hiroshi ^a   Murata, Sakae ^a   Odawara, Akio ^a   Sasaki, Haruhiko ^a   Nagao, Taku ^a,b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

2,3 dihydro 1,5 benzothiazepin 4(SH) one; 3 arylglycidic ester; Aminothiophenol; Antihypertensive activity; Platelet aggregation; Vasodilation

Indexed keywords

3 ACETOXY 5 [2 (DIMETHYLAMINO)ETHYL] 2,3 DIHYDRO 8 METHYL 2 (4 METHYLPHENYL) 1,5 BENZOTHIAZEPIN 4(5H)ONE; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DILTIAZEM; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM ANTAGONISM; DOG; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; HYPERTENSION; MALE; NONHUMAN; RAT; REACTION ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION;

EID: 17744416525     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.45.1008     Document Type: Article

References (23)

1. a) Godfraind T., Miller R., Wibo M., Pharmacol. Rev., 38, 321-416 (1986);
2. b) Circulation. Suppl., 80, IV1-IV188 (1989).
3. a) Triggle D. J., Langs D. A., Janis R. A., Med. Res. Rev., 9, 123-180 (1989);
4. b) Bossert F., Mayer H., Wehinger E., Angew. Chem., Int. Ed. Engl., 20, 762-769 (1981);
5. c) Atwal K. S., Rovnyak G. C., Kimball S. D., Floyd D. M., Moreland S., Swanson B. N., Gougoutas J. Z., Schwartz J., Smillie K. M., Malley M. F., J. Med. Chem., 33, 2629-2635 (1990);
6. d) Drugs of the Future, 15, 671-673 (1990).
7. Inoue H., Konda M., Hashiyama T., Otsuka H., Takahashi K., Gaino M., Date T., Aoe K., Takeda M., Murata S., Narita H., Nagao T., J. Med. Chem., 34, 675-687 (1991).
8. a) Kugita H., Inoue H., Ikezaki M., Konda M., Takeo S., Chem. Pharm. Bull., 19, 595-602 (1971);
9. b) Inoue H., Takeo S., Kawazu M., Kugita H., Yakugaku Zasshi, 93, 729-732 (1973);
10. Abe K., Inoue H., Nagao T., ibid., 108, 716-732 (1988).
11. a) Hashiyama T., Inoue H., Takeda M., J. Chem. Soc., Perkin Trans. 1, 1984, 1725-1732;
12. b) Idem., ibid., 1985. 421-427.
13. Randvere F. V., Fr. Patent 1502178 (1967) [Chem. Abstr., 70, 11629y (1969)].
14. Tsuda K., Sakamoto S., Matuda H., Kanno T., Yakugaku Zasshi, 60, 462 (1940).
15. Kiyomoto A., Sasaki Y., Odawara A., Morita T., Circ. Res., 52 (suppl I): 115-119 (1983).
16. a) Odawara A., Kikkawa K., Katoh M., Toryu H., Shimazaki T., Sasaki Y., Circ. Res., 78, 643-649 (1995);
17. ++-antagonist action. The mechanism is under investigation.
18. Dondzila F. A., Restivo A. R., Yale L., U.S. Patent 346020 (1969) [Chem. Abstr., 70, 87832q (1969)].
19. Born G. V. R., Nature (London), 194, 927-929 (1962).
20. Sheldrick G. M., "SHELXS-86; A program for the solution of crystal structures," University of Goettingen, Germany, 1986.
21. Sheldrick G. M., "SHELXL-93; A program for crystal structure refinement," University of Goettingen, Germany, 1993.
22. Flack H. D., Acta Crystallogr., Sect. A; Found. Crystallogr., A39, 876-881 (1983).
23. The atomic parameters, bond lengths, and bond angles are available from one of the authors (H. I.) upon request.